A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)

Shah, M. A.; Kortmansky, Jeremy; Gönen, Mithat; Tse, Archie; Lefkowitz, Robert A.; Kelsen, David; Colevas, Dimitrios; Winkelman, J.; Yi, Sandy; Schwartz, Gary K.

doi:10.1200/jco.2004.22.14_suppl.4027

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, its co-administration with irinotecan and cisplatin for relapsed gastric or oesophageal cancer was evaluated in a phase I clinical trial with remarkable efficacy results. Five out of 11 gastric cancer patients and two out of three oesophageal cancer patients achieved a partial response (PR) [136]. Future double-blind controlled phase II clinical studies are expected to confirm Flavopiridol's activity in this population.…”

Section: Inhibitors Of Cyclin-dependant Kinases-flavopiridol (Alvocidmentioning

confidence: 96%

Targeted therapy for oesophageal cancer: an overview

Syrigos

Zalonis

Κοττέας

et al. 2008

Cancer Metastasis Rev

View full text Add to dashboard Cite

Oesophageal cancer (OC), is an aggressive cancer constituting a major cause of cancer-related deaths worldwide. Recent advances in surgical techniques, incorporation of new therapeutic approaches -- adjuvant/neoadjuvant chemoradiotherapy -- and integration of new cytotoxic drugs into the management of oesophageal cancer have increased the response rate percentages to 40-50%, with minor impact on the overall survival. The need for an efficacious therapy with minimal toxicity along with a better understanding of molecular pathways of oesophageal carcinogenesis has led to the development of novel anticancer agents. These agents have targeted mechanisms of action such as: (1) inhibitors of the ErbB receptor family, (2) vascular endothelial growth factor (VEGF) inhibitors, (3) selective inhibitors of cycloxygenase-2, (4) matrix metalloproteinase inhibitors, (5) cell-cycle regulators, and (6) promoters of apoptosis. The incorporation of these agents into combined modality treatment schedules for advanced and early stage tumors together with the identification of patients who will most likely benefit will provide novel opportunities in the treatment of oesophageal cancer.

show abstract

Section: Inhibitors Of Cyclin-dependant Kinases-flavopiridol (Alvocidmentioning

confidence: 96%

Targeted therapy for oesophageal cancer: an overview

Syrigos

Zalonis

Κοττέας

et al. 2008

Cancer Metastasis Rev

View full text Add to dashboard Cite

show abstract

“…Despite evidence of the in vivo activity of single‐agent flavopiridol in patients with CRC,164 no efficacy was observed in a recent Phase II trial of 20 chemotherapy‐naïve patients with CRC treated with a biweekly, 72‐hour infusional schedule 165. In contrast, flavopiridol has reportedly augmented irinotecan‐mediated effects in both preclinical and early clinical trials,166, 167 and Phase II assessments of this combination are underway.…”

Section: Novel Biologically Targeted Therapeuticsmentioning

confidence: 99%

New systemic frontline treatment for metastatic colorectal carcinoma

Braun

Achterrath²,

Wilke

et al. 2004

Cancer

View full text Add to dashboard Cite

“…A phase I study has evaluated the combination of flavopiridol, irinotecan, and cisplatin in patients with advanced refractory GC and EC, with clear signs of activity. In this limited study five out of eleven patients with GC and two out of three with EC achieved a PR [70]. This encouraging PR rate is higher than that expected for patients treated with the combination of cisplatin and irinotecan in this refractory population.…”

Section: Cell-cycle Inhibitorsmentioning

confidence: 54%

Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies

et al. 2006

View full text Add to dashboard Cite

Upper gastrointestinal malignancies are major causes of morbidity and mortality worldwide. Despite the results of recent clinical trials with new chemotherapy strategies showing encouraging activity and efficacy, the prognosis of patients with advanced gastric, gastroesophageal junction and esophageal cancer remains poor. The demonstration in other tumor types of the effectiveness of anticancer drugs with a targeted mechanism of action, interfering with pathways involved in tumor growth and spread, has opened a new era in drug development. In patients with advanced colorectal cancer, the introduction of epidermal growth factor receptor (EGFR) inhibitors and antiangiogenic agents has resulted in a significant increase in antitumor activity and survival. These targeted agents are currently being also evaluated in other tumor types including these upper gastrointestinal malignancies. These targeted agents include, among others, EGFR inhibitors, antiangiogenic agents, cell-cycle inhibitors, apoptosis promoters, and matrix metalloproteinase (MMP) inhibitors. The emerging data from the clinical development of these compounds provide novel opportunities in the treatment of these common malignancies that will probably translate into clinical benefit for patients with these diseases. This review describes the preclinical rationale and the current status of the clinical development of these compounds in patients with gastroesophageal neoplasms.

show abstract

A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)

Cited by 7 publications

References 0 publications

Targeted therapy for oesophageal cancer: an overview

Targeted therapy for oesophageal cancer: an overview

New systemic frontline treatment for metastatic colorectal carcinoma

Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies

Contact Info

Product

Resources

About